Buscar
Mostrando ítems 21-30 de 102
Hepatic bile formation: Canalicular osmolarity and paracellular and transcellular water flow
(American Society for Pharmacology and Experimental Therapeutics, 2019-12)
The purpose of this minireview is to show that a new paradigm is developing regarding hepatic bile flow. The focus thus far has been on carrier-mediated transport of bile acids and other solutes, such as glutathione, which ...
Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis
(Pergamon-Elsevier Science Ltd, 2019-10)
Lipopolysaccharide (LPS) from Gram (-) bacteria induces inflammatory cholestasis by impairing the expression/localization of transporters involved in bile formation (e.g., Bsep, Mrp2). Therapeutic options for this disease ...
Impact of impurity on kinetic estimates from transport and inhibition studies
(AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS, 2008)
Although in vitro transport/inhibition studies are commonly performed on impure drug candidates to screen for pharmacokinetic properties in early development, quantitative guidelines concerning acceptable impurity levels ...
Efflux of bile acids in Lactobacillus reuteri is mediated by ATP
(Springer, 2011-11-10)
Purpose of work: To study whether an active bile acid (BA) efflux occurs in Lactobacillus reuteri CRL 1098 as well as the nature (ATP or proton motive force [PMF] mediated primary transport) of the BA extrusion mechanism. ...
Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications
(Portland Press, 2011-12)
UDCA (ursodeoxycholic acid) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies. Its use has expanded to other kinds of hepatic diseases, and even to extrahepatic ones. Such versatility ...